Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

NCT06722183 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Futibatinib orally administered
DRUG: Tislelizumab (i.v. 200mg)

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler